Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤$7.38 million cash at September 30, 2026, up from $5.16 million year-end
- ➤Cash resources expected to fund operations through second quarter of 2027
- ➤SYMON-II enrollment exceeded target, reaching 777 evaluable patients
- ➤FDA 510(k) submission planned for Symphony IL-6 in first half of 2027
- ➤Alternative cartridge manufacturing site established ahead of October 23 deadline
Expert Statements
Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics
“The third quarter marked significant progress for Bluejay as we advanced several critical elements toward regulatory submission and commercialization. With SYMON-II enrollment completed, important manufacturing milestones achieved, and U.S. supply chain infrastructure enhanced, I believe that we have meaningfully reduced several key development and operational risks. Going forward, our focus remains on completing clinical and analytical validation and preparing for company's planned FDA submission in the first half of 2027.”
Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics
“Our achievements in clinical development and manufacturing have positioned us to focus on the next critical phase of execution towards commercial readiness. We remain committed to disciplined capital allocation, regulatory progress and building a scalable diagnostic platform with the potential to address important unmet needs in critical care.”
ACTON, MA / ACCESS Newswire / November 12, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid, near-patient testing solutions for critical care, today reported financial results for the quarter ended September 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress for the Symphony™ platform. During the quarter and subsequent weeks, Bluejay achieved several important milestones, including completion of enrollment in its SYMON-II clinical validation study, establishment of an alternative manufacturing facility ahead of a contractual deadline, and continued advancement of its U.S. manufacturing and commercialization infrastructure.
"The third quarter marked significant progress for Bluejay as we advanced several critical elements toward regulatory submission and commercialization," said Neil Dey, President and Chief Executive Officer. "With SYMON-II enrollment completed, important manufacturing milestones achieved, and U.S. supply chain infrastructure enhanced, I believe that we have meaningfully reduced several key development and operational risks. Going forward, our focus remains on completing clinical and analytical validation and preparing for company's planned FDA submission in the first half of 2027."
Get started
Create a free account to read the full story.